Changing Malaria Drug Policy in Kenya
Author Information
Author(s): Amin Abdinasir, Zurovac Dejan, Kangwana Beth B, Greenfield Joanne, Otieno Dorothy N, Akhwale Willis S, Snow Robert W
Primary Institution: Kenya Medical Research Institute/Wellcome Trust Research Programme
Hypothesis
What are the challenges and processes involved in changing the national malaria drug policy to artemisinin-based combinations in Kenya?
Conclusion
The transition to artemisinin-based combination therapy for malaria treatment in Kenya was achieved relatively quickly, but future policy changes must consider various financial, political, and legislative challenges.
Supporting Evidence
- The transition from sulphadoxine-pyrimethamine to artemether-lumefantrine was announced in April 2004.
- Over 60 million US$ was approved by the Global Fund to procure artemether-lumefantrine.
- The implementation of the new drug policy took over 32 months due to various challenges.
Takeaway
This study talks about how Kenya changed its malaria treatment from an old drug to a new one that works better, but it took a long time because of many problems.
Methodology
The study used narrative descriptions from discussions with stakeholders, reports, and other documents to outline the drug policy change process.
Potential Biases
Potential bias from stakeholders involved in the policy change process may affect the narrative.
Limitations
The study may not capture all milestone dates and discussions between key actors involved in the policy change.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website